Nitrates, most commonly nitroglycerin, are a frontline treatment for chest pain and acute heart failure in emergency settings, but ACLS protocols flag several situations where giving them can make a patient worse. The main contraindications are hypotension (systolic blood pressure below about 90 mmHg), right ventricular infarction, recent use of phosphodiesterase-5 (PDE-5) inhibitors or riociguat, and severe aortic stenosis. Each of these reflects a different way that the blood-pressure-lowering effect of nitrates can become dangerous rather than helpful, and the reasoning behind them is worth understanding in detail.
How Nitrates Lower Blood Pressure and Why That Matters
Nitroglycerin works primarily by relaxing the smooth muscle in blood vessel walls. At typical clinical doses, it has a much stronger effect on veins than on arteries. Relaxing veins causes blood to pool in the peripheral circulation instead of returning to the heart, which reduces the volume of blood filling the ventricles before each beat. In cardiology terms, this is a reduction in “preload.” The result is lower pressure inside the heart chambers and less work for the heart to do, which is exactly what you want in a patient with pulmonary congestion or ischemic chest pain. Classic catheterization data from patients with congestive heart failure showed that sublingual nitroglycerin dropped end-diastolic pressure from about 19 to 8 mmHg while having little effect on total systemic vascular resistance, confirming that venous dilation was the dominant mechanism at standard doses.
1PubMed. Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure. Differential effects of nitroprusside, phentolamine, and nitroglycerin on cardiac function and peripheral circulationAt higher doses or in patients with elevated arterial stiffness, nitroglycerin begins to dilate arteries as well, reducing afterload. Research on patients with varying levels of ventricular function found that those with excessive arterial stiffness and compromised hearts experienced a predominant afterload reduction and an increase in stroke volume, while normotensive patients with intact hearts mainly saw preload reduction.
2PubMed. Bolus intravenous nitroglycerin predominantly reduces afterload in patients with excessive arterial elastanceThis dose-dependent behavior is clinically important. At lower doses, nitroglycerin acts principally as a venodilator, while at higher doses, a mixed venous and arterial dilating effect emerges. Patients with the most severe left ventricular dysfunction tend to derive the most hemodynamic benefit from that mixed effect.
3PubMed Central. Comparison of intravenous nitroglycerin and sodium nitroprusside in acute myocardial infarctionEvery contraindication on the ACLS list ties back to the same core problem: if you reduce the blood returning to the heart or lower vascular resistance in a patient who cannot compensate, cardiac output crashes and blood pressure plummets. The specific contraindications identify the patients most vulnerable to that chain of events.
Right Ventricular Infarction
This is probably the most tested contraindication in ACLS courses, and the one providers are drilled on most thoroughly. When the right ventricle is damaged by a heart attack, it loses its ability to pump blood effectively into the lungs. The right ventricle depends heavily on adequate blood return from the veins to maintain any meaningful output. Nitrates, by pooling blood in the veins and slashing preload, can essentially starve an already struggling right ventricle of the filling pressure it needs. The consequence can be a sudden and severe drop in blood pressure.
Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) recommend withholding nitrates when right ventricular myocardial infarction is present, specifically because decreasing preload in a heart with an already compromised right ventricular ejection fraction can reduce cardiac output and precipitate hypotension.
4Emergency Medicine Journal. Adverse events from nitrate administration during right ventricular myocardial infarction: a systematic review and meta-analysisIn practice, right ventricular infarction should be suspected in any patient presenting with an inferior ST-elevation myocardial infarction, particularly when they show hypotension, jugular venous distension, and clear lung fields. Right-sided ECG leads, especially V4R, are the key diagnostic step. The important clinical takeaway is that chest pain alone does not automatically mean “give nitroglycerin.” The location and type of infarct matter enormously.
PDE-5 Inhibitors and Riociguat
Sildenafil, tadalafil, and vardenafil are PDE-5 inhibitors prescribed for erectile dysfunction and, in some formulations, pulmonary hypertension. They amplify the same nitric oxide signaling pathway that nitroglycerin activates. When a patient takes a nitrate on top of a PDE-5 inhibitor, the combined vasodilation can be extreme and unpredictable, producing profound and potentially life-threatening hypotension.
ACLS guidelines are specific about the timing. Sildenafil and vardenafil have shorter half-lives, so the standard teaching is to avoid nitrates for at least 24 hours after their use. Tadalafil lasts longer. A pharmacokinetic study demonstrated that the hemodynamic interaction between tadalafil and sublingual nitroglycerin persisted for a full 24 hours but was no longer detectable at 48 hours.
5PubMed. Time course of the interaction between tadalafil and nitratesThis means providers need to ask about tadalafil use within the past 48 hours before administering any nitrate. The question is straightforward to ask, but patients sometimes do not volunteer the information, either because of embarrassment or because they do not realize the interaction is dangerous. Making the question routine and matter-of-fact during any chest pain evaluation is the simplest way to avoid this problem.
Riociguat, a soluble guanylate cyclase stimulator used in pulmonary arterial hypertension, interacts with nitrates through a similar but distinct mechanism. Both riociguat and nitrates boost cyclic GMP signaling in vascular smooth muscle, and the combination can cause profound hypotension.
6Europe PMC. Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial HypertensionRiociguat is less commonly encountered than sildenafil or tadalafil, but patients on it are often seriously ill with pulmonary hypertension, making hypotension especially dangerous. In any patient with known pulmonary hypertension on advanced therapies, verifying the medication list before reaching for nitroglycerin is essential.
Severe Aortic Stenosis and Fixed Cardiac Output
Severe aortic stenosis creates a fixed obstruction to blood leaving the left ventricle. The heart has to generate very high pressures to push blood through the narrowed valve, and systemic blood pressure is maintained largely through compensatory increases in vascular resistance. Nitrates lower that vascular resistance and reduce venous return simultaneously, but the narrowed valve prevents the heart from increasing its output to compensate. The theoretical result is a dangerous drop in blood pressure with no way for the heart to recover on its own.
This contraindication has been part of cardiology teaching for decades. An older but frequently cited study described the mechanism, noting that nitrates are contraindicated in severe aortic stenosis because of the risk of precipitating profound hypotension, though it also acknowledged that the risk was “theoretical yet unproven” at the time.
7The American Journal of Cardiology. Mechanism of nitroglycerin effect in valvular aortic stenosisSince then, the contraindication has remained in guidelines despite limited high-quality evidence quantifying the actual risk. Some clinicians have noted that carefully titrated nitrates in moderate aortic stenosis may be tolerated, but the ACLS framework treats severe stenosis as an absolute contraindication, and in an emergency setting where you cannot carefully titrate and monitor over an extended period, that bright-line rule is practical and appropriate. Hypertrophic obstructive cardiomyopathy follows similar logic: the obstruction worsens when the ventricle is less full, and nitrates make the ventricle less full.
Hypotension and Volume Depletion
The most intuitive contraindication is simple: do not give a blood-pressure-lowering drug to someone whose blood pressure is already dangerously low. ACLS protocols typically set the threshold at a systolic blood pressure below 90 mmHg, or more than 30 mmHg below the patient’s known baseline. Any patient who is already hypotensive from any cause, whether it is hemorrhage, sepsis, dehydration, or cardiogenic shock, is at risk of further hemodynamic collapse if you add nitrate-induced vasodilation on top of their existing problem.
Volume-depleted patients deserve special attention. Someone who is severely dehydrated or has had significant fluid losses already has reduced venous return. Nitrates will exaggerate that deficit by further pooling blood peripherally. Even a patient with a borderline-normal systolic pressure who is clearly volume depleted may respond to nitroglycerin with a precipitous drop. Clinical judgment matters here: the 90 mmHg cutoff is a guideline, not a magic number. A patient sitting at 95 mmHg who looks pale and dry with a fast heart rate may be a poor candidate for nitrates regardless of technically clearing the threshold.
Bradycardia is another consideration worth noting. A patient with a very slow heart rate who is already struggling to maintain cardiac output is at heightened risk from any further reduction in filling pressures. ACLS guidelines generally advise caution with nitrates in the setting of marked bradycardia or tachycardia for the same fundamental reason: the heart may not be able to compensate for the drop in preload.
What Happens When Nitrates Cause Hemodynamic Trouble
When a patient drops their blood pressure after receiving nitroglycerin, the first steps are straightforward. Stop the nitrate immediately if it is an infusion, or recognize that sublingual nitroglycerin’s effects will wear off within minutes. Place the patient supine with legs elevated to encourage venous return, and give an intravenous fluid bolus. Most episodes of nitrate-induced hypotension respond to these simple measures because the drug’s half-life is short.
In more severe cases, particularly in patients with right ventricular infarction where the hypotension can be dramatic, aggressive volume resuscitation may be needed. Vasopressors are a last resort if fluids alone do not restore adequate perfusion. The key principle is restoring preload: get blood back to the heart. In the setting of right ventricular infarction, this often means giving more fluid than you might think is appropriate in a cardiac patient, because the right ventricle needs extra filling pressure to generate any meaningful output through compromised muscle.
A study of high-dose intravenous nitroglycerin for severe decompensated heart failure found that symptomatic hypotension developed in roughly 3% of patients, even when doses averaged around 6.5 mg.
8Annals of Emergency Medicine. Feasibility and Outcome Assessment of Treatment of Severe Decompensated Heart Failure With High-Dose NitroglycerinThat low rate is reassuring when nitrates are used in the right patients, but it also underscores why the contraindications exist: the goal is to keep that complication rate near zero by screening out the patients most vulnerable to it before you ever open the drug.
Tolerance During Prolonged Infusions
Nitrate tolerance, sometimes called tachyphylaxis, is a well-known phenomenon that affects patients receiving continuous intravenous nitroglycerin infusions, typically in an ICU setting rather than during initial ACLS management. Over hours of continuous infusion, the body’s vascular smooth muscle becomes progressively less responsive to nitroglycerin, requiring higher and higher doses to achieve the same hemodynamic effect.
In one study comparing intravenous nitroglycerin to an alternative vasodilator in patients with congestive heart failure, tachyphylaxis developed in 60% of patients during nitroglycerin infusion over a 24-hour period. Pulmonary capillary wedge pressure, which started at about 25 mmHg before treatment, dropped to about 19 mmHg at 24 hours with nitroglycerin, a meaningful but attenuated reduction compared to baseline effects.
9PubMed Central. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failureTolerance is not exactly a contraindication in the ACLS sense, but it has practical implications. A patient who has been on a nitroglycerin drip for a day may not respond to additional boluses the way you expect. It also means that the dose that was working earlier may stop working, prompting unnecessary dose escalation that sets the patient up for rebound effects when the infusion is eventually stopped. The classic teaching to prevent tolerance is to provide a “nitrate-free interval” of at least eight to twelve hours per day, though in acute settings, this is not always feasible.
Methemoglobinemia at High Doses
Nitroglycerin is metabolized to nitric oxide and inorganic nitrite, and nitrite can oxidize hemoglobin to methemoglobin, a form that cannot carry oxygen effectively. At standard clinical doses, this is not a concern. But when intravenous nitroglycerin is used at high doses for extended periods, clinically significant methemoglobinemia becomes a possibility.
A study examining this association found that patients who developed elevated methemoglobin levels had received substantially higher cumulative doses of intravenous nitroglycerin than those with normal levels. The mean infusion rate in the abnormal group was about 350 micrograms per minute with a cumulative dose averaging roughly 3,400 mg, compared to about 240 micrograms per minute and 1,600 mg in the normal group. The authors concluded that clinically significant methemoglobinemia is uncommon during IV nitroglycerin infusion, but becomes more likely when large doses are administered.
10PubMed. Association of methemoglobinemia and intravenous nitroglycerin administrationThis is primarily a concern for ICU teams managing prolonged high-dose drips rather than for providers in the initial ACLS response. But if a patient on a nitroglycerin infusion develops cyanosis that does not improve with supplemental oxygen and pulse oximetry readings that seem discordant with the clinical picture, methemoglobinemia should be on the differential. A co-oximetry measurement on an arterial blood gas will confirm the diagnosis. Treatment with methylene blue is effective when the methemoglobin level is high enough to cause symptoms.
Situations That Feel Like Contraindications but Are Not
A few clinical scenarios cause providers to hesitate with nitrates even though guidelines do not list them as true contraindications. One common source of uncertainty is inferior myocardial infarction without confirmed right ventricular involvement. The teaching about right ventricular infarction is so firmly drilled that some providers avoid nitrates entirely in any inferior MI. The actual guideline concern is specific to right ventricular involvement, which is why checking right-sided leads matters before making the decision.
Another area of unnecessary caution involves patients on long-acting oral nitrates like isosorbide mononitrate. Some providers worry that adding sublingual nitroglycerin on top of an existing oral nitrate regimen is contraindicated. In fact, these patients are already tolerant to some degree of nitrate effect, and additional nitroglycerin for acute symptoms is expected and appropriate per standard prescribing. The concern is additive hypotension, which should be monitored, but the combination is not contraindicated the way PDE-5 inhibitors are.
Patients with headache after nitroglycerin sometimes prompt concern, but headache is a common and expected side effect of nitrate-induced vasodilation in the cranial vasculature. It is uncomfortable but not dangerous and is not a reason to withhold future doses if the clinical indication remains.
Asking the Right Questions Before Reaching for Nitroglycerin
In an acute chest pain or heart failure presentation, a handful of quick assessments cover the major contraindications. Checking the blood pressure is obvious and automatic. Asking about PDE-5 inhibitor use within the past 24 to 48 hours requires actually asking the patient (or checking the medication list if the patient cannot communicate). Looking at the ECG for signs of inferior or right ventricular infarction takes seconds. Reviewing the history for known severe aortic stenosis or hypertrophic cardiomyopathy is part of the initial assessment. And assessing for signs of volume depletion through clinical appearance, heart rate, and response to positioning gives you a sense of whether the patient can tolerate preload reduction.
None of these steps takes long, and all of them can prevent a well-intentioned intervention from turning into a crisis. The contraindications list is not arbitrary; each item represents a specific physiological vulnerability where the normal benefit of nitrate therapy flips into harm. Understanding why each contraindication exists makes them easier to remember and, more importantly, easier to apply to patients who do not fit neatly into textbook descriptions.